pharma · Relapsed/Refractory Diffuse Large B-cell Lymphoma · Non-muscle invasive bladder cancer (NMIBC)
Shanghai Antengene Corporation
Shanghai Antengene Corporation Limited
Shanghai Antengene Corporation is a pharma organization headquartered in SAINT-LAURENT, CN. Primary therapeutic focus areas include Relapsed/Refractory Diffuse Large B-cell Lymphoma, Non-muscle invasive bladder cancer (N
SAINT-LAURENT, CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- SAINT-LAURENT, CN
- Programs
- 3
- Drugs
- 8
- Patents
- 53
EG-70 (phase 1)
Phase 2 · small molecule · Superficial Bladder Cancer
EG-70 (phase 1) for Superficial Bladder Cancer is a Phase 2 program (small_molecule) at Shanghai Antengene Corporation Limited with 1 ClinicalTrials.gov record(s).
Internal code EG-70-101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Shanghai Antengene Corporation Limited
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Superficial Bladder Cancer
- Status
- active
- Trials
- 1